Oncology
FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera: A New Option for Erythrocytosis
FDA approval of rusfertide creates a systemic option for adults with polycythemia vera whose erythrocytosis has traditionally required phlebotomy, with or without cytoreductive therapy.
Dr. Abu Bakar · September 7, 2026 · 6 min